N/A Inhaled Nitric Oxide Treatment of Extremely Preterm Infants with Delayed Pulmonary Vascular Transition to Reduce the Incidence of Broncho-pulmonary Dysplasia

NCT03576885

Inhaled Nitric Oxide Treatment of Extremely Preterm Infants with Delayed Pulmonary Vascular Transition to Reduce the Incidence of Broncho-pulmonary Dysplasia

Associated Conditions

Neonatal, Pulmonary

Principal Investigator

Sponsor

Mallinckrodt Company

This research is being conducted to see if using inhaled nitric oxide (a gas that is delivered along with oxygen) in extremely preterm infants with pulmonary hypertension will decrease the long-term lung problems and improve their outcomes.

This study is currently enrolling.